Head and neck cancer

Recommendations for Head and Neck Cancer Awareness Month from the American Board of Oral and Maxillofacial Surgery

Retrieved on: 
星期四, 四月 11, 2024
Education, Throat, Sore throat, Patient, Cancer, CAQ, Mouth, Woman, Certification, Oral cancer, Risk, Neck, Head and neck cancer, Nose, Tobacco, Love, DMD, DDS, FACS, EDM, Oral and maxillofacial surgery, HPV, Head, Reconstructive surgery, Quality of life, Dentistry

CHICAGO, April 11, 2024 /PRNewswire/ -- The Executive Board and Diplomates of the American Board of Oral and Maxillofacial Surgery (ABOMS) recognize Head and Neck Cancer Awareness Month in April. Many ABOMS Diplomates are experts in head and neck cancer, which account for about 4 percent of cancer cases in the United States. They see this month as an opportunity to educate the public.

Key Points: 
  • To promote public awareness of head and neck cancer, board-certified oral and maxillofacial surgeons share facts and tips
    CHICAGO, April 11, 2024 /PRNewswire/ -- The Executive Board and Diplomates of the American Board of Oral and Maxillofacial Surgery (ABOMS) recognize Head and Neck Cancer Awareness Month in April.
  • Many ABOMS Diplomates are experts in head and neck cancer, which account for about 4 percent of cancer cases in the United States.
  • The American Board of Oral and Maxillofacial Surgery (ABOMS) certifies oral and maxillofacial surgeons who have proven their qualifications and expertise through education, training, and a thorough examination process.
  • Patients looking for a highly qualified oral and maxillofacial surgeon for their oncology team should look for this kind of specialized training and certification.

Vaccinex Reports 2023 Financial Results and Provides Corporate Update

Retrieved on: 
星期二, 四月 2, 2024
8-K, Research, Cash, Prevalence, HNSCC, Patient, Biomarker, Microglia, Sale, Nature, Form 10-K, Cancer, Neuroinflammation, Neuron, Neoplasm, Cognition, Drug development, Head and neck cancer, Astrocyte, PFS, Security, Neurodegenerative disease, Pharmaceutical industry

ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the fourth quarter ended December 31, 2023 and provided a corporate update on key programs.

Key Points: 
  • ROCHESTER, N.Y., April 02, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the fourth quarter ended December 31, 2023 and provided a corporate update on key programs.
  • Vaccinex achieved several important clinical milestones for pepinemab in both Alzheimer’s disease and Head and Neck Cancer.
  • Financial Results for the Year Ended December 31, 2023:
    Cash and Cash Equivalents and Marketable Securities.
  • The Company effected a 1-for-15 reverse stock split in Q3 2023 and 1-for-14 reverse stock split in Q1 2024.

Microbix Unveils Test Controls for Head and Neck Cancer

Retrieved on: 
星期一, 三月 11, 2024
Woman, EQA, Sunnybrook Health Sciences Centre, QAP, TSX, Cancer, Throat, Exhibition, Dartmouth–Hitchcock Medical Center, IHC, Quality control, Mouth, Diagnosis, Tongue, Accreditation, Histology, Palate, Papillomaviridae, HPV, OTCQX, PCR, QC, Laboratory, Research, Nose, Head and neck cancer, Medical imaging

While HPV is best known for causing cancers of the cervix in women, this virus family also causes cancer in other bodily tissues.

Key Points: 
  • While HPV is best known for causing cancers of the cervix in women, this virus family also causes cancer in other bodily tissues.
  • Such further types of HPV-driven cancer include those of the “Head and Neck,” collectively tumours inside and behind the nose, throughout the mouth (including the tongue, gums, and palate), all sections of the throat, and the voice box.
  • Unfortunately, a lack of standardized and reproducible reference samples makes it challenging to control the recommended test workflows for diagnosing such cancers.
  • These standardized and reproducible tissue-oriented test controls will then be added to Microbix’s catalogue of QAPs, expanding its activities into support of oncology workflows alongside its wide range of infectious disease test controls.

Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial

Retrieved on: 
星期二, 二月 13, 2024
Neoplasm, Head and neck cancer, Cetuximab, Toxicity, Doctor of Philosophy, Research fellow, Immunotherapy, SAB, University, Health, Associate, HNC, Neck, Assistant, Escape Room, SCCHN, Moores Cancer Center, Associate professor, Focus group, Oncology, Immunity, Metastasis, Biomarker, Science, Tumor microenvironment, Communication, Division, Drug resistance, MD, Lead, Patient, Publication, Cancer, Pharmaceutical industry

REHOVOT, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) --  Purple Biotech Ltd.("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it convened a Scientific Advisory Board (SAB) focusing the discussions on NT219’s indication in recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).

Key Points: 
  • “Their recognition of the critical unmet need in recurrent and metastatic head and neck cancer provides further support and momentum to our development program.
  • Now that we have determined the recommended Phase 2 dose, we are prepared to move to our next phase of development.
  • We look forward to the head and neck cancer SAB’s continued guidance and support.”
    Head & Neck Cancer SAB Members Include:
    Douglas Adkins, MD – Dr. Adkins is a Professor of Medicine and Director, Head and Neck and Thyroid Medical Oncology, at the Siteman Cancer Center, Washington University School of Medicine.
  • He is a nationally recognized expert in head and neck cancer known for his commitment to advancing patient care through clinical research.

Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
星期一, 十一月 13, 2023
Encephalitis, Nature, HD, Eurosport 1, Patient, Research, Neuron, Dementia, Conference, Cash, ORR, Cognition, Drug discovery, Cancer, Doctor of Philosophy, Form 10-Q, Glial fibrillary acidic protein, FCMI, Prevalence, Astrocyte, GFAP, Microglia, Blood, Head and neck cancer, Three Months, Completeness, Risk, PFS, Merck, L.L.C, SEMA4D, Clinical trial, Security, Drug, Drug development, Patent, SIGNAL, Biomarker, Brain, CCR8, Plasma, Disease, Private placement, Neurodegenerative disease, Private, Neoplasm, G protein-coupled receptor, Cryptocurrency, Pharmaceutical industry, Medical imaging, Vaccine, HNSCC

ROCHESTER, N.Y., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update on progress in key programs.

Key Points: 
  • ROCHESTER, N.Y., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update on progress in key programs.
  • The potential impact of the AD program on Vaccinex valuation and financial resources make this Vaccinex’s most important near-term catalyst.
  • On August 22, 2023, Vaccinex completed a Private Placement and issued approximately 0.20 million shares1 of common stock for aggregate proceeds of $0.7 million.
  • Similarly, on September 22, 2023, Vaccinex completed a Private Placement and issued approximately 0.25 million shares of common stock for aggregate proceeds of $0.6 million.

Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting

Retrieved on: 
星期五, 十一月 3, 2023
Technology, Genetics, Health Technology, Software, Biotechnology, Health, Pharmaceutical, General Health, Oncology, SNV, Taxane, Plasma, Stomach, Paclitaxel, Bladder cancer, Research, Cancer, Poster, HNSCC, Pharmacokinetics, SITC, Immunotherapy, Drug discovery, Biopsy, Annual general meeting, Head and neck cancer, RECIST, Biliary tract, Society, Therapy, Liquid biopsy, Patient, Neoplasm, Prostate, PR, Pharmaceutical industry, Medical imaging, Illumina

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced data from two poster presentations being presented tomorrow, November 4, 2023, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA.

Key Points: 
  • Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced data from two poster presentations being presented tomorrow, November 4, 2023, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA.
  • The study calls for the involvement of certified labs, highlighting the need for stringent quality management and regulatory alignment.
  • The poster titled, “FID-007: Nanoencapsulated Paclitaxel Derived from a Novel Nano-Drug Delivery Platform,” highlights progress for Fulgent Pharma’s lead therapeutic oncology candidate, FID-007, in various cancers.
  • Preliminary clinical data suggests FID-007 may have anti-tumor activity in heavily pre-treated patients across various tumor types.

Viewpoint will Partner with Oncologists and Physicians to Explore the Evolution of Head and Neck Cancer Treatment

Retrieved on: 
星期二, 十月 3, 2023
Head and neck cancer, Otorhinolaryngology, Oncology, Viewpoint, Cancer, Health, Research, Patient, Physician, Atmosphere, Immunotherapy, Disease, Dentistry, Neck

MIAMI, Oct. 3, 2023 /PRNewswire-PRWeb/ -- Viewpoint, the acclaimed television program hosted by Dennis Quaid, will be partnering with oncologists and physicians to delve into the groundbreaking advancements in the field of Head and Neck cancer treatment. Filming is scheduled to commence in early 2024.

Key Points: 
  • Viewpoint's production team is currently in the planning stages for this pivotal episode, which is set to air at a later date in 2024.
  • Head and Neck cancers have long presented significant challenges to both patients and medical professionals.
  • The production team behind Viewpoint is dedicated to delivering a comprehensive and informative exploration of Head and Neck cancer treatment, aiming to increase awareness and understanding.
  • The collaboration with reputable oncologists and physicians will offer a unique perspective on the evolving landscape of Head and Neck cancer treatment, highlighting the importance of early detection, patient care, and the promise of improved outcomes.

Precision Biologics Announces the United States Patent and Trademark Office (USPTO) has granted a Patent for its Lead Monoclonal Antibody, NEO-201, For the Treatment of Human Carcinomas

Retrieved on: 
星期一, 十月 2, 2023
Head and neck cancer, Clinical trial, Cervical cancer, Cancer, Immunotherapy, Endometrial cancer, NSCLC, Precision, Regulatory T cell, Patent, Patient, Immunoglobulin G, Conference, Safety, Disease, Pharmaceutical industry, Pembrolizumab

NEO-201 is a humanized IgG1 monoclonal antibody with multiple mechanisms of action.

Key Points: 
  • NEO-201 is a humanized IgG1 monoclonal antibody with multiple mechanisms of action.
  • It has been shown previously to kill cancer cells expressing its target (truncated glycans) which is expressed in numerous cancers; however, it does not bind to most normal tissues.
  • Data from the ongoing Phase 2 trial was recently presented at CRI-ENCI-AACR 7th International Cancer Immunotherapy Conference Sept 22, 2023, Milan, Italy.
  • Additional data regarding the effects of NEO-201 on reducing gMDSCs will be presented at the upcoming SITC Annual Meeting in San Diego in early November.

Vaccinex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
星期一, 八月 14, 2023
PDAC, Completeness, Rochester, Trastuzumab, Pathology, Merck Group, Cash, Astrocyte, Patient, FCMI, Observation, H. Lee Moffitt Cancer Center & Research Institute, Private placement, Three Months, Eurosport 1, University, Brain, Research, Lecanemab, TME, Motivation, Drug discovery, Neoplasm, FDA, B cell, Safety, Cognition, Neuron, ICI, G protein-coupled receptor, Metastatic breast cancer, DC1, Cancer, Lung cancer, CCR8, Immunotherapy, Antibody, PFS, ARIA, Publication, MBC, Biomarker, Microglia, SEMA4D, Security, ORR, HD, Head and neck cancer, Drug development, Nature, SIGNAL, Avelumab, Neurodegenerative disease, Pfizer, CO, Breast cancer, Pharmaceutical industry, Medical imaging, Vaccine, Cryptocurrency, HNSCC, Merck

ROCHESTER, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update on progress in key programs. .

Key Points: 
  • Expect to Complete 12-months treatment in June, 2024
    ROCHESTER, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update on progress in key programs.
  • Over the last few months, Vaccinex achieved several important clinical milestones for pepinemab in both Alzheimer’s disease and Head and Neck Cancer.
  • In the first segment, completed on May 12, 2023, Vaccinex sold approximately 7.9 million shares of common stock for aggregate proceeds of $2.96 million.
  • For further details on Vaccinex’s financials, refer to its Form 10Q filed August 14, 2023 with the S.E.C.

Phase 1 Study Indicates Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells Plus N-803 May Induce Tumor Regression in Advanced Head-and-Neck Cancer Patients

Retrieved on: 
星期一, 七月 10, 2023
Oncology, Health, Infectious Diseases, Clinical Trials, Pharmaceutical, Biotechnology, HNC, AACR, CIML, Progression-free survival, Platinum, Cyclophosphamide, Head, Woman, NK, Cell, American Head, Immunotherapy, PFS, Assistant, Harvard Medical School, Organic acid, ORR, Patient, Ipilimumab, HNSCC, HPV, Safety, Head and neck cancer, Disease, Dana–Farber Cancer Institute, Pharmaceutical industry, Medical imaging, Vaccine, Medicine

The results indicate the potential for a new treatment approach for the disease in advanced cases that currently have extremely poor prognoses.

Key Points: 
  • The results indicate the potential for a new treatment approach for the disease in advanced cases that currently have extremely poor prognoses.
  • “It was exciting to observe some tumor regression among heavily pre-treated patients with advanced head-and-neck cancer using a live cell therapy approach,” said Dr. Hanna.
  • The study showed that tumor regression was associated with expansion of the NK cell type with cytolytic activity, CD56dimCD16+ NK cells, that target and kill tumor cells.
  • “It is encouraging that allogeneic CIML NK cells supported by N-803 may induce tumor regression in advanced head-and-neck cancer patients,” said Patrick Soon-Shiong, M.D., Executive Chairman and Global Chief Scientific and Medical Officer at ImmunityBio.